Journal article
The association between dairy food intake and the incidence of diabetes in Australia: the Australian Diabetes Obesity and Lifestyle Study (AusDiab)
NM Grantham, DJ Magliano, A Hodge, J Jowett, P Meikle, JE Shaw
Public Health Nutrition | CAMBRIDGE UNIV PRESS | Published : 2013
Abstract
Objective Several studies have suggested that dairy food may reduce the risk of obesity and metabolic abnormalities but few have been able to conclusively demonstrate that it reduces the risk of diabetes. The aim of the present analysis was to investigate if dairy food intake independently reduces the risk of diabetes. Design The Australian Diabetes Obesity and Lifestyle Study (AusDiab) is a national, population-based, prospective survey conducted over 5 years. Baseline measurements included a 121-item FFQ, anthropometrics and an oral glucose tolerance test. Setting Forty-two randomly selected clusters across Australia. Subjects Adults aged ≥25 years who participated in the baseline survey a..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC
Funding Acknowledgements
Funding from The Dairy Health and Nutrition Consortium (DHNC) is gratefully acknowledged. The DHNC is a consortium of Tatura Milk Industries & Bega Cheese, National Foods, Fonterra Australia, Parmalat Australia, Dairy Australia, Geoffrey Gardiner Foundation, Murray Goulburn Co-operative, Warrnambool Cheese & Butter Factory, and Dairy Innovation Australia. The AusDiab study, co-coordinated by the Baker IDI Heart and Diabetes Institute, gratefully acknowledges the generous support given by: the National Health and Medical Research Council (NHMRC grant 233200); the Australian Government Department of Health and Ageing; Abbott Australasia Pty Ltd; Alphapharm Pty Ltd; AstraZeneca; Bristol-Myers Squibb; the City Health Centre, Diabetes Service, Canberra; the Department of Health and Community Services - Northern Territory; the Department of Health and Human Services - Tasmania; the Department of Health - New South Wales; the Department of Health - Western Australia; the Department of Health - South Australia; the Department of Human Services - Victoria; Diabetes Australia; Diabetes Australia Northern Territory; Eli Lilly Australia; the Estate of the Late Edward Wilson; GlaxoSmithKline; the Jack Brockhoff Foundation; Janssen-Cilag; Kidney Health Australia; the Marian & FH Flack Trust; Menzies Research Institute; Merck Sharp & Dohme; Novartis Pharmaceuticals; Novo Nordisk Pharmaceuticals; Pfizer Pty Ltd; the Pratt Foundation; Queensland Health; Roche Diagnostics Australia; Royal Prince Alfred Hospital, Sydney; Sanofi Aventis; and Sanofi Synthelabo. D.J.M. is supported by a Victorian Cancer Agency Public Health Fellowship. J.E.S. is supported by an NHMRC Senior Research Fellowship (540103). All authors declare no conflict of interest with regard to this manuscript. All authors contributed to the conception and design of the study. N.M.G. conducted the analysis and drafted the manuscript. All authors were involved in the preparation of the final manuscript. All authors were involved in the preparation of the final manuscript. For their invaluable contribution to the set-up and field activities of AusDiab, the authors are enormously grateful to A. Allman, B. Atkins, S. Bennett, A. Bonney, S. Chadban, M. de Courten, M. Dalton, D. Dunstan, T. Dwyer, H. Jahangir, D. Jolley, D. McCarty, A. Meehan, N. Meinig, S. Murray, K. O'Dea, K. Polkinghorne, P. Phillips, C. Reid, A. Stewart, R. Tapp, H. Taylor, T. Whalen, F. Wilson and P. Zimmet. Finally, the authors thank the AusDiab participants for volunteering their time to participate in the study.